» Articles » PMID: 39077069

Feasibility of a Percutaneous and Non-Fluoroscopic Procedure for Transcatheter Mitral Valve Edge-to-Edge Repair

Overview
Date 2024 Jul 30
PMID 39077069
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Transcatheter edge-to-edge repair (TEER) of the mitral valve has emerged as an alternative treatment for mitral regurgitation (MR). However, the high radiation exposure during the process has been associated with multiple adverse effects for medical staff. In this study, we assessed the feasibility and safety of TEER performed solely under the echocardiographic (echo) guidance.

Methods: Between April 2021 to August 2021, we retrospectively collected characteristics of 23 patients with MR who underwent TEER under echocardiographic guidance exclusively. Follow-up evaluations were performed at 1- , 3-months and 1-year post procedure.

Results: All 23 patients (mean age, 66.1 12.1 years; 65.2% males) successfully underwent echo-guided TEER, with 22 patients under transesophageal echo (TEE) guidance and 1 patient under transthoracic echo (TTE) guidance for severe esophageal stenosis. Of the patients, 60.9% received 1 implant and 39.1% received 2 implants. The median total procedural time was 130 (interquartile range, IQR: 90-150) min and the device procedure time was 73 (IQR: 58-100) min. The median length of stay was 6 (IQR: 5-9) days. At 3-months follow-up, 63.6% of patients had an MR 1+ and 90.9% had an MR 2+ ( 0.001 vs. baseline). Improvement in functional status was observed, with 40.9% of patients classified as New York Heart Association (NYHA) functional class I and 45.5% as NYHA functional class II ( 0.001 compared to baseline) at 3-months. At 1-year follow-up, 90.4% maintained MR reduction with MR 2+ ( 0.001 vs. baseline). Single leaflet device attachment (SLDA) occurred in one patient (4.3%) 1-week post procedure.

Conclusions: This retrospective, single-center, and pilot study demonstrates the feasibility, safety, and low complication rates of TEER guided solely by echocardiography. Our findings support the systematic use of echocardiography as the sole guidance modality for TEER, highlighting its potential as an alternative to fluoroscopy-guided procedures. Further multicenter and comparative studies are warranted to confirm these results and provide a more comprehensive evaluation of this approach.

Citing Articles

Technique and Preliminary Results of Sole-echocardiography-guided Tricuspid Transcatheter Edge-to-edge Repair without the Use of Fluoroscopy.

Gao M, Shi H, Wang C, Meng H, Wang J, Zhu D Rev Cardiovasc Med. 2024; 25(11):413.

PMID: 39618851 PMC: 11607490. DOI: 10.31083/j.rcm2511413.

References
1.
Otto C, Nishimura R, Bonow R, Carabello B, Erwin 3rd J, Gentile F . 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020; 77(4):450-500. DOI: 10.1016/j.jacc.2020.11.035. View

2.
Obadia J, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N . Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018; 379(24):2297-2306. DOI: 10.1056/NEJMoa1805374. View

3.
Whitlow P, Feldman T, Pedersen W, Lim D, Kipperman R, Smalling R . Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012; 59(2):130-9. DOI: 10.1016/j.jacc.2011.08.067. View

4.
Kong P, Zhao G, Zhang Z, Zhang W, Fan T, Han Y . Novel Panna Guide Wire Facilitates Percutaneous and Nonfluoroscopic Procedure for Atrial Septal Defect Closure: A Randomized Controlled Trial. Circ Cardiovasc Interv. 2020; 13(9):e009281. DOI: 10.1161/CIRCINTERVENTIONS.120.009281. View

5.
Wang S, Meyer D, Schumacher B . Inheritance of paternal DNA damage by histone-mediated repair restriction. Nature. 2022; 613(7943):365-374. PMC: 9834056. DOI: 10.1038/s41586-022-05544-w. View